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Abstract The antipyretic analgesics, paracetamol, and
non-steroidal anti-inflammatory agents NSAIDs are one of
the most widely used classes of medications in children.
The aim of this review is to determine if there are any
clinically relevant differences in safety between ibuprofen
and paracetamol that may recommend one agent over the
other in the management of fever and discomfort in chil-
dren older than 3 months of age.
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Methods: a review of the current literature
Pre-school children suffer frequent episodes of illness
leading to more primary care consultations than any other
age group (McCormick et al. 1991). The most common
reasons are coughs, colds, earaches and fevers (Hay and
Heron 2005), with fever as the primary presentation for
these illnesses.
The underlying cause of childhood fever is generally
benign, and fever has a beneficial effect in terms of fighting
infection (Sullivan and Farrar 2011). However, fever can
cause distress and discomfort in children, leading to a high
degree of parental concern. For febrile children without any
indication of a serious underlying condition (‘low-risk’
fever), and key among the updated recommendations, is the
need to treat symptoms of the fever with a focus on com-
forting the child, rather than on achieving normothermia.
National guidelines recommend home management
(NICE 2013; Sullivan and Farrar 2011; Chiappini et al.
2012; Oteman et al. 2008) and childhood fever associated
with discomfort or pain can be easily treated with over-the-
counter (OTC) antipyretic (and analgesic) agents such as
paracetamol (acetaminophen) and ibuprofen. Both agents
are generally well tolerated and given equal status in both
national and international guidelines. Current advice in the
UK also states that paracetamol should be used to treat
post-immunization fever in babies after their meningo-
coccal B injections at age 2 and 4 months; in this instance,
ibuprofen is not currently recommended.
In light of some of the above recommendations, parents
of young children and health-care professionals may per-
ceive paracetamol as being safer than ibuprofen. For
pharmacists, who are likely to be safety driven, this per-
ception may be fuelled by a lack of differentiation between
the gastrointestinal (GI) safety profile of OTC and pre-
scription (Rx) doses of NSAIDs. Most pharmacists also
consider NSAIDs as a class, rather than isolating individual
analgesics and assessing their GI safety profiles. Com-
bined, this behaviour encourages the perception of
ibuprofen having a poorer GI safety profile than paraceta-
mol rather than being on a sliding scale of risk.
For paediatrics, first-line treatment for mild-to-moderate
pain is either ibuprofen or paracetamol. Aspirin should not
be given to children under 16 years unless on the advice of
a doctor, because there is a very small risk that children can
develop a condition called Reye’s syndrome if they are
given aspirin when they have a viral illness. If pain relief is
inadequate, second-line treatment is switching from one
agent to the other, and third-line is treatment is to alternate
between the two. Preliminary results of ongoing research
into the prescribing habits of doctors and recommendations
made by pharmacists have identified the following trends:
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• Ibuprofen and paracetamol are the commonly pre-
scribed analgesics.
• For fever, paracetamol is the most commonly pre-
scribed for both paediatric and adult patients.
• For pain, ibuprofen is the most commonly prescribed
for paediatrics (followed by paracetamol); however
they share the top spot for adult patients.
• For inflammation, ibuprofen is the most commonly
prescribed for both paediatric and adult patients.
When ibuprofen is administered at therapeutic doses in
children of up to 10 mg/kg body weight every 6–8 h the
possible adverse events are, as for other NSAIDs related to
inhibition of cyclo-oxygenase (COX-1 and COX-2) and
prostaglandin (PG) pathways, gastrointestinal bleeding,
renal impairment, asthma and hepatic toxicity. Rainsford
et al. (1997) have reviewed the safety of paracetamol and
ibuprofen administered in adults at therapeutic dosages. The
authors concluded that both agents were safe as used in
clinical trials, and that there are no statistically significant
differences between paracetamol and ibuprofen in reports of
adverse events in any organ system, irrespective of the type
or frequency of event. Across a range of clinical studies in
which either ibuprofen or paracetamol were treatments of
primary interest, the overall percentage of patients having a
minor adverse event was about 10% with paracetamol
compared with 8% with ibuprofen, for drug exposure up to
30 days, which is not unexpected for events that are moni-
tored prospectively. However, with such ubiquitous usage of
both agents, the increased reporting of rare or idiosyncratic
side effects and consequences of unintentional (or inten-
tional) overdosing is a likely occurrence.
Safety
Safety is clearly a primary consideration in the choice of
antipyretic, and both ibuprofen and paracetamol have been
associated with safety issues, not all of which appear to be
evidence based. Overall, ibuprofen and paracetamol are
considered to have similar safety and tolerability profiles in
paediatric fever, and this has been confirmed in meta-
analyses (Southey et al. 2009; Pierce and Voss 2010). For
example, a recent meta-analysis including 19 evaluable
studies found no significant difference between the two
agents in the incidence of adverse events in paediatric
patients (0.82; 95% CI 0.60–1.12) (Pierce and Voss 2010)
(Fig. 1).
However, a number of specific safety issues are often
raised for both agents, which may impact on recommen-
dations and prescribing practice. The question arises as to
whether these concerns are evidence based, or have arisen
due to medical ‘myths’ or ‘dogma.’
Specific safety issues
Gastrointestinal effects
The mechanism of acute NSAID-induced upper gastroin-
testinal complications (UGIC’s) is likely due to the
combined result of topical effects and inhibition of both
COX-1 and COX-2. Inhibition of COX-1 reduces
microvascular blood flow; topical effects are due to lipid
solubility and low pKa which renders NSAIDs a detergent
and an uncoupler of mitochondrial oxidative phosphory-
lation: all these effects are dose dependent. The local
effects of COX-2 inhibition are uncertain.
Dose-dependent gastrointestinal (GI) toxicity (e.g.
bleeding) in association with NSAID treatment in adults is
well documented in ‘at-risk’ patients (Bjarnason 2013). In
adults, the rate of gastrointestinal symptoms associated
with low-dose ibuprofen (1200 mg/day) is similar to that
reported with paracetamol and placebo, but less than with
aspirin (Moore et al. 1999). One study in which approxi-
mately 2000 adult patients taking NSAIDs were compared
with 11,500 controls in a nested case–control analysis
showed that the average relative risk of significant bleeding
with NSAID is 3.0. There is, however, a hierarchy of risk
among NSAIDs, with ibuprofen ranking among the lowest
(Garcia Rodriguez 2001). A further randomized controlled
trial of ibuprofen, paracetamol or a combination tablet in
adults with osteoarthritis showed that paracetamol 3 g/day
may cause similar degrees of asymptomatic blood loss (as
measured by a drop in haemoglobin), as ibuprofen
1200 mg/day and the combination of the two agents
appeared to be additive (Doherty et al. 2011).
The evidence in adults suggests that at over-the-counter
(OTC) doses, symptomatic GI side effects with ibuprofen
are comparable with placebo, and treatment is well toler-
ated and largely free of gastric damage (Bjarnason 2013).
While there are fewer data regarding GI effects in febrile
children, in one of the largest trials of ibuprofen and
paracetamol, the risk of GI bleeding was low (7.2 per
100,000), with no statistically significant difference in GI
bleeding between the two treatment groups (p = 0.31). The
four cases of GI bleeding reported in this study occurred in
children previously treated with ibuprofen; all were man-
aged conservatively with no endoscopy being required
(Lesko and Mitchell 1995a, b). This finding is occasionally
cited as a potential cause for concern, despite the lack of
significance relative to paracetamol. However, since this
early study, other studies have confirmed that (UGIC’s) are
rare events in children treated with NSAIDs, with a low
absolute risk of about 2.4 UGIC incidents per 10,000
children presenting to emergency departments (Grimaldi-
Bensouda et al. 2010; Bianciotto et al. 2013). Of these,
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minor gastrointestinal side effects are the most commonly
reported in clinical trials raising concerns regarding
potential adverse gastrointestinal effects with the use of
NSAIDs generally.
In addition, in their case–controlled study of children
admitted to hospital via emergency departments for acute
conditions over an 11-year period, Bianciotto found no
significant difference in the risk of UGICs with paraceta-
mol (adjusted OR 2.0, 95% CI 1.5–2.6) compared with
ibuprofen (adjusted OR 3.7, 95% CI 2.3–5.9) (Bianciotto
et al. 2013), although the adjusted OR for NSAIDs in
Grimaldi-Bensouda et al’s study reached 8.2 (95% CI
2.6–26.0), with one-third of cases attributable to exposure
to NSAIDs administered at therapeutic doses (although
limited dataset and recall bias could not be excluded).
A consequence of the perceived association of NSAIDs
and UGIC’s is the common advice to take ibuprofen with
food (or fluids such as milk), the rationale being that such
co-administration exerts a ‘protective’ effect in the GI
tract. This has a particular impact for OTC use in childhood
fever, where children may feel too unwell to eat or drink.
However, the need for NSAIDs to be taken with food has
never been properly studied in humans. It is possible that
certain foods may have negative as well as positive effects.
Food delays the achievement of peak levels of NSAIDs and
so impacts on efficacy, leading to the suggestion that it may
be more appropriate to advocate that OTC ibuprofen be
taken on a fasting stomach to achieve a rapid onset of
action and to avoid the use of an ‘extra’ dose because the
speed of action did not meet expectations (Rainsford and
Bjarnason 2012). Given that OTC antipyretics are given for
a short time period to manage childhood fever, and that
rapid onset of action and symptom relief are important
aspects, the advice to take ibuprofen with food may not be
appropriate for this setting.
Asthma
Both ibuprofen and paracetamol are commonly used in the
management of acute feverish childhood illnesses. The
incidence of NSAID- or paracetamol-triggered asthma in
children is thought to be less frequent than in adults. In a
Fig. 1 Forest plot of amended log odds ratios comparing proportion of children experiencing at least one adverse event for paracetamol versus
ibuprofen. Negative numbers denote that the odds rations in the paracetamol treatment group are lower than the ibuprofen groups (reproduced
with kind permission from Pierce and Voss 2010)
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randomized controlled trial in febrile asthmatic children,
those who received ibuprofen were less likely to be hos-
pitalized and significantly less likely to require outpatient
visits for asthma compared with children who received
paracetamol (Lesko et al. 2002). Debley et al. (2005)
investigated the prevalence of ibuprofen-sensitive asthma
in 127 children aged 6–18 years with mild-to-moderate
asthma. Out of 100 children who completed a bron-
choprovocation challenge study, 2 children (prevalence
2%) met the criteria for ibuprofen-sensitive asthma [95%
confidence interval (CI) 0.2, 7.0].
Aspirin-induced asthma (AIA) is a well-recognized and
distinct clinical syndrome of asthma and rhinitis affecting
up to 5% of asthmatic children aged 10 years and older,
peaking around the third decade of life. Symptoms of
asthma and rhinitis occur about 30 min to 3 h after
ingestion of aspirin or other NSAIDs. Episodes of asthma
are severe and can even be life threatening; however, many
patients are often unaware of their sensitivity either
because they have never taken aspirin or have developed
AIA in adulthood after years of apparent tolerance (Babu
and Salvi 2004). Therefore, the use of aspirin in both the
paediatric and adult asthmatic populations should largely
be discouraged.
Although the name would suggest a direct link solely
to aspirin exposure, there is cross sensitivity to all
classes of NSAIDs, which may be of concern to OTC
users who suffer from asthma and those who prescribe it
to them. The mechanism of sensitivity is thought to be
related to COX-1 inhibition favouring lipo-oxygenase
activity, which in turn indirectly causes an increase in
the production of leukotrienes and subsequent bron-
choconstriction. However, the prevalence and cross
reactivity to other analgesics have been difficult to assess
due to differences in the trial methods. There is
emerging evidence that suggests paracetamol may also
contribute to the exacerbation of asthma or asthma-re-
lated adverse events, and patients who have AIA can
also to be sensitive to paracetamol, albeit less severely
(Jenkins et al. 2004).
Despite a theoretical potential association between
ibuprofen and asthma, evidence suggests a low risk for
asthma-related morbidity associated with ibuprofen use in
children (Kanabar et al. 2007). Ibuprofen does not appear
to exacerbate asthma in children without a history of
aspirin sensitivity and may in fact be associated with a
lower risk of exacerbation than paracetamol (Kanabar et al.
2007). A cross-sectional analysis using the Third National
Health and Nutrition Examination Survey has shown that
paracetamol use in adults was associated with an increased
risk of asthma and chronic obstructive pulmonary disease
and decreased lung function (McKeever et al. 2005).
Increasing frequency of paracetamol use (C14 days per
month) was positively associated with an increased risk of
newly diagnosed adult-onset asthma (p = 0.006). A further
study has shown that the incidence of asthma in infrequent
users (\monthly) and monthly, weekly and daily users was
1.06, 1.22, 1.79 and 2.38, respectively (p = 0.0002)
(Shaheen et al. 2000).
The underlying mechanisms for the risk of asthma and
impaired lung function have been studied by Eneli and
colleagues who have shown that paracetamol decreases the
concentration of glutathione, which results in the vulnera-
bility of the asthmatic patient to oxidative stress (Eneli
et al. 2005). Low levels of glutathione lead to the inability
to counteract oxidative stress and a defective processing of
disulphide bonds that are key in antigen presentation.
Furthermore, lack of inhibition of COX-2 by paracetamol
and the subsequent synthesis of PGE2 promote immuno-
logical activity with a T-helper cell type 2 response that
establishes an allergic tendency in the immune response to
various stimuli.
There is growing concern regarding a potential link
between paracetamol and lung injury, bronchoconstriction
and asthma development, particularly due to maternal use
of this analgesic during pregnancy. Frequent paracetamol
use (most days or daily) during late pregnancy
(20–32 weeks) was associated with an increased risk of
wheezing in the offspring at 30–42 months compared with
paracetamol non-users (Shaheen et al. 2002).
Paracetamol use has also been implicated in asthma
development and the increasing incidence of asthma in
adults and children in epidemiological, observational and
pathophysiological studies (reviewed in McBride 2011;
Farquhar et al. 2010; Eneli et al. 2005; Beasley et al.
2008, 2011). and more recently in a prospective birth
cohort study (Kreiner-Moller et al. 2012).
Although it is difficult to prove a causal pathway
between paracetamol use and subsequent long-term con-
ditions, some experts now state that there is ‘overwhelming
evidence’ of a link between paracetamol and asthma
(Holgate 2011) and have warned about the potential for
paracetamol intolerance in some asthmatic patients (Eneli
et al. 2005; McBride 2011). Given the widespread use of
paracetamol in children, there has been a call for causation
to be proved or disproved in adequately powered placebo-
controlled trials (Holgate 2011), and clearly more research
in this field is required.
In conclusion, evidence suggests that the risk of asthma-
related morbidity with ibuprofen use is low in febrile
children. The therapeutic benefit of ibuprofen as an anti-
pyretic and analgesic outweighs any putative risk of acute
bronchospasm in children with asthma (Kauffman and
Lieh-Lai 2004). Furthermore, regular use of ibuprofen has
been associated with better lung function (McKeever et al.
2005).
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Cardiovascular effects
The use of certain COX-2 inhibitors was associated with an
increased risk of adverse cardiovascular events in adults,
leading to a withdrawal from the market (Conaghan 2012).
However, cardiovascular events associated with COX-2
inhibitors have not been reported in children (Foeldvari
et al. 2009).
Unintentional ingestion of ibuprofen
Between 2001 and 2008, more than 22,000 children aged
5 years or under visited US emergency departments for
ingestion of over-the-counter analgesics other than parac-
etamol (Bond 2012).
Between 2010 and 2013, ibuprofen accounted for 16%
of US emergency department visits for unsupervised over-
the-counter liquid medication exposures in young children.
(Lovegrove et al. 2015).
In Spain, 38 out of 2157 cases of childhood poisoning
were from ibuprofen (Mentegi et al. 2006).
Reports of complications following ibuprofen overdose,
particularly in children, are rare. The vast majority of
individuals who overdose on ibuprofen alone have no, or
only mild, symptoms (Volans et al. 2003). Fatal overdose
in adults is extremely rare and generally related to com-
plicating factors such as the presence of other drugs. Cases
of symptomatic overdose in children have been reported
following ingestion of over 440 mg/kg (Hall et al. 1986),
but in general the risk of serious complications following
ibuprofen overdose is low (Argentieri et al. 2012).
Hepatotoxicity and risk of overdose
with paracetamol
One of the main concerns with regard to paracetamol use is
hepatotoxicity due to overdose. With therapeutic dosing,
paracetamol is predominantly metabolized by conjugation
with sulphate and glucuronide. Approximately, 5–10% of
the drug is oxidized by CYP450-dependent pathways
(mostly CYP2E1 and CYP3A4) to a toxic, electrophilic
metabolite, N-acetyl-p-benzoquinone imine (NAPQI)
(Corcoran et al. 1980). NAPQI is detoxified by glutathione
and eliminated in the urine or bile. The NAPQI that is not
detoxified may bind to hepatocytes and produce cellular
necrosis. Usually, because of the relatively small amount of
NAPQI formed and the adequate supply of glutathione,
paracetamol has an excellent safety profile.
A threshold paracetamol dose associated with hepatic
toxicity in children has been difficult to establish because
of inaccurate recollection of the ingested dose, doses
administered during several days and prolonged release
products. Rumack and Matthew in their landmark 1975
study did not indicate a minimum dose for toxicity, but
emphasized prolongation of the half-life of paracetamol
from liver toxicity (Rumack and Matthew 1975). The
Rumack and Matthew nomogram of paracetamol levels
and time after dose was developed for prediction of risk in
acute intoxications, so that a low level does not eliminate
the possibility of toxicity caused by chronic ingestion of
paracetamol.
Reports of liver toxicity in paediatric patients have
suggested that a minimal, single paracetamol dose of
120–150 mg/kg of body weight may be associated with
hepatoxicity (Henretig et al. 1989; Alander et al. 2000).
Hepatotoxicity with paracetamol at recommended doses
(Iorio et al. 2013; Savino et al. 2011; Ferrajolo et al. 2010)
and in the setting of an acute overdose (Heubi et al. 1998;
Hameleers-Snijders et al. 2007; Mahadevan et al. 2006) has
also been reported in children, and there is significant
concern over the possibility of paracetamol-related hep-
atitis due to chronic overdose following either the
administration of supratherapeutic doses or too frequent
administration of appropriate single doses (Kubic et al.
2009; Sullivan and Farrar 2011; Rivera-Penera et al. 1997).
Heubi et al. reported a mortality rate of 55% in 47 cases,
with half the deaths in children aged less than 2 years. It
was determined that the dosage administration ranged from
60 to 240 mg/kg/day administered for between 1 and
42 days (Heubi et al. 1998). The conclusion based on this
and other investigations is that paracetamol can cause
serious hepatotoxicity in children administered dosages as
low as 125–150 mg/kg/day when taken for 2–4 days
(Rivera-Penera et al. 1997) with accumulation of the drug
being a possible cause (Nahata et al. 1984).
Kearns et al. have suggested that a child susceptible to
toxicity is likely to be less than 2 years of age, has been
taking 90 mg/kg/day or more of paracetamol for more than
1 day and who is acutely malnourished and dehydrated as a
consequence of vomiting, diarrhoea or decreased fluid and
nutrient intake (Kearns et al. 1998). It is suggested that in
this combination of factors, the mechanisms for detoxifi-
cation of the hepatotoxic metabolite of paracetamol are
more likely to be deficient.
In addition, a recent UK study found that, even when
administered under current instructions, underweight chil-
dren are at risk of receiving approximately twice, and
average weight children up to 133% of, the recommended
single and cumulative daily dose of paracetamol; this has
led to recently proposed changes in dosing recommenda-
tions (Eyers et al. 2012a, b). Two reports of hepatotoxicity
in association with dosages reported to be in the therapeutic
range (Heubi et al. 1998; Makin et al. 1995) may represent
inaccurate memory of the administered doses or a narrower
paracetamol therapeutic window because of associated
conditions. Such conditions might include inherited
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differences in hepatic enzyme activity, malnutrition, etha-
nol ingestion, drug interactions or concomitant medical
disorders.
It is important to remember that children with a family
history of hepatic toxicity to paracetamol have an increased
risk of developing a toxic reaction. The health-care pro-
vider should consider paracetamol toxicity in any child
who has received paracetamol with signs of acute hepatic
dysfunction, even if paracetamol levels are not in the toxic
range. If the levels are in the toxic range after long-term
treatment with paracetamol, it is an ominous finding
associated with a high risk of mortality.
Finally, clinical signs of liver disease, such as fever or
abdominal pain, are often treated with paracetamol. Whe-
ther hepatic injury from underlying conditions, such as
viral infections or metabolic diseases, is exacerbated by
paracetamol remains uncertain. Many reported cases of
severe hepatotoxicity in children have been attributed to
cumulative toxicity from repeated doses rather than acute
intoxication from a single massive overdose.
Renal effects
NSAIDs have been associated with the development of
acute kidney injury, which is thought to be related to COX
inhibition leading to changes in haemodynamics and acute
interstitial nephritis (AIN). While it is unlikely that pros-
taglandins have much impact on children with normal
circulating volume, in individuals with volume depletion,
their role as vasodilators becomes more important to
maintain adequate renal perfusion. Blocked prostaglandin
synthesis leads to unchecked vasoconstriction of the
afferent arteriole, resulting in reduced GFR and eventually
renal ischaemia and acute tubular necrosis (Lameire et al.
2005; Taber and Mueller 2006).
There were no incidences of acute renal failure in a large
practitioner-based population study which included 55,785
children treated with ibuprofen (Lesko and Mitchell
1995a, b) or in the Boston Collaborative Fever study which
included 27,065 febrile children randomized to ibuprofen
(Lesko and Mitchell 1999). A further study by the same
author found that, with short-term use of ibuprofen, the risk
of less severe renal impairment is small and not signifi-
cantly greater than with paracetamol (Lesko and Mitchell
1997).
Similarly, a large-scale paediatric study by Ashraf and
colleagues found no incidences of renal conditions in over
31,000 children treated with either ibuprofen or paraceta-
mol (Ashraf et al. 1999). There have, however, been rare
case reports of reversible renal insufficiency in children
with febrile illnesses treated with ibuprofen or other
NSAIDs, largely associated with volume depletion (Krause
et al. 2005; Moghal et al. 2004; Ulinski et al. 2004).
Dehydration is a known risk factor for NSAID-induced
acute renal failure, and this has led some experts to rec-
ommend caution in ibuprofen use in children with
dehydration or pre-existing renal disease (Sullivan and
Farrar 2011; Chiappini et al. 2012). Recently, a retro-
spective chart review of 1015 children with acute kidney
injury (AKI) managed over an 11.5-year period concluded
that 27 cases (2.7%) were associated with NSAID use
(predominantly ibuprofen), and that younger children
(\5 years of age) were more likely to require dialysis or
admission into ICU (Misurac et al. 2013). This retrospec-
tive study raises obvious concerns; however, it has a
number of important limitations which make these con-
clusions questionable. Most importantly, patients with a
history of volume depletion, an independent risk factor for
AKI, were not excluded from the analysis. The most
common presenting symptoms given for children in this
study were vomiting and decreased urine output, and the
majority of patients defined as having NSAID-associated
AKI had a history of volume depletion. It is unclear whe-
ther these dehydrated patients may have developed AKI
irrespectively of NSAID use.
In clinical practice, the author’s experience is that renal
problems arising out of short-term usage (i.e. less than
7 days) of ibuprofen in feverish children are an unlikely
occurrence; nevertheless, caution (and common sense)
should be applied when administering any agent that may
interfere with renal function in a volume-depleted or multi-
organ failure child.
Rarely, patients may also present with manifestations of
systemic hypersensitivity reactions. Children receiving
NSAIDs may also present with nephrotic syndrome (Per-
azella and Markowitz 2010; Alper et al. 2002).
Preventative strategies should include avoiding NSAIDs
and/or monitoring those at high risk, including children
with volume depletion, pre-existing renal disease or con-
comitant use of other nephrotoxic drugs.
Soft tissue infections
Several reports have suggested an association between
severe soft tissue superinfection and the use of NSAIDs. In
particular, ibuprofen was implicated when its use in chil-
dren with varicella was linked with the subsequent
development of invasive Group A streptococcal infections
(Wattad et al. 1994; Petersen et al. 1996).
This concern prompted a retrospective cohort study in
which data from over 7000 children with varicella were
examined (Choo et al. 1997). This study showed that 89
superinfections developed among 7013 cases of varicella.
Out of 169 children receiving ibuprofen within 180 days of
varicella diagnosis, only 4 developed a superinfection (OR
1.5 (95% CI 0.3–4.9)). Compared with children who were
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naive to ibuprofen, those who were dispensed ibuprofen in
the month prior to varicella were 3.1 times more likely to
be diagnosed with a superinfection (95% CI = 0.1–19.7; p=
0.31). This study concluded that the infrequent dispensing
and skin superinfection significantly limited the power of
the study and that over 54,000 children with varicella
would have to be studied to detect a relative risk of 2 with
a = 0.05 and 80% power.
Conclusions
Despite the widespread use of ibuprofen and paracetamol,
thankfully the rate of severe toxicity in children remains
rare. Meta-analyses confirm that the safety and tolerability
profiles of paracetamol and ibuprofen in managing chil-
dren’s pain and fever are similar, and that both drugs are
associated with specific rare adverse events, which are
difficult to detect and quantify in all but the largest clinical
trials.
However, despite published evidence to the contrary,
globally paracetamol is perceived as having better GI, renal
and respiratory safety and overall better tolerability than
ibuprofen. In turn, ibuprofen is perceived as having better
GI safety than aspirin and its safety profile, particularly for
short-term use is poorly understood among health-care
practitioners and the public. This is likely due to the fol-
lowing factors:
1. A lack of distinction from other NSAID’s, resulting in
a ‘‘class effect’’ bias.
2. Ingrained negative perceptions from the time of
undergraduate or postgraduate training.
3. Lack of awareness of the impact of the dose (Rx versus
OTC).
4. A misconception that ibuprofen needs to be taken with
food and a perceived gastro protective effect of food—
whereas the opposite is true, in that administration
with food slows the speed of absorption and may
interfere with its efficacy.
5. It is also possible that newly qualified HCPs may be
aware of the current state of knowledge with regard to
ibuprofen safety and tolerability, but may lack the
confidence to put this knowledge into practice—and
this needs further exploration.
6. Finally, patients (and parents of young children) tend
to display medication-sparing behaviour and have little
understanding of the impact of delayed treatment with
suboptimal doses on analgesic efficacy.
The aim of this review has been to assess the evidence
with respect to clinical and safety factors which would aid
HCPs in recommending one agent over another when
advising parents of children with pain and/or fever, and the
author’s conclusion is that for short-term usage (i.e. for less
than 7 days), both paracetamol and ibuprofen have equally
good safety and tolerability profiles, and when efficacy data
is considered alongside safety, ibuprofen may be more
preferable in providing relief from discomfort, fever and
pain.
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